Accepted Manuscript

Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?

Stefan Mühlebach



PII: DOI: Reference:	S0169-409X(18)30163-7 doi:10.1016/j.addr.2018.06.024 ADR 13334
To appear in:	Advanced Drug Delivery Reviews
Received date:	3 April 2018
Revised date:	21 June 2018
Accepted date:	26 June 2018

Please cite this article as: Stefan Mühlebach , Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?. Adr (2018), doi:10.1016/j.addr.2018.06.024

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Stefan Mühlebach,

Regulatory Challenges of Nanomedicines and their follow-on versions: Generics or Similars?

Themed issue ADDR: Drug Nanoparticles and Nano-Cocrystals: from Production and Characterization to Clinical Translation

Title and authors affiliation

Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach?

Chair of the Non Biological Complex Drug WG, c/o Lygature, Jaarbeursplein 6, 3521 AL Utrecht NL

Regulatory Science Lead Non Biological Complex Drugs at Vifor Pharma Ltd, Flughofstrasse 61 • P.O. Box • CH-8152 Glattbrugg Switzerland

University of Basel, Department of Pharmaceutical Sciences, Division of Clinical Pharmacy & Epidemiology • Hospital Pharmacy Spitalstrasse 26 • CH-4031 Basel (Switzerland)

Mail: stefan.muehlebach@unibas.ch

Download English Version:

https://daneshyari.com/en/article/10157339

Download Persian Version:

https://daneshyari.com/article/10157339

Daneshyari.com